View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharnext S.C.A 배당 및 자사주 매입배당 기준 점검 0/6Pharnext S.C.A 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Negative equity (-€32m). Earnings have declined by 7.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 2228x increase in shares outstanding). Revenue is less than US$1m (€172k revenue, or US$181k). Market cap is less than US$10m (€34.0 market cap, or US$35.8). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€10.1k market cap, or US$11.0k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.8m revenue, or US$2.0m).공시 • May 09Pharnext SA, Annual General Meeting, Jun 10, 2024Pharnext SA, Annual General Meeting, Jun 10, 2024. Location: 14 rue de la republique, suresnes France공시 • Feb 01Pharnext SA announced that it has received €41.188458 million in fundingPharnext SA announces private placement of 30,783,601,087 shares for an issue price of €0.001338 per shares for gross proceeds of €41,188,458 on January 31, 2024.New Risk • Dec 27New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$173). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).공시 • Jan 04Pharnext Strengthens Its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of QualityPharnext SA announces the appointment of Scott Johnson as VP, Head of Quality. This appointment further strengthens the Company's Senior Leadership Team. Scott has more than 15 years of experience in quality management and compliance within the healthcare sector. He joins from Oyster Point Pharma, where he was Head of Quality Assurance. There, he established and implemented a comprehensive quality management system and oversaw all quality-related functions during the submission of an NDA application and successful launch of Oyster Point's first commercial product. Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance. He has also held roles at Johnson & Johnson and Warner Chilcott. Scott has a BA in Organizational Management from the Eastern University, St. David's, PA and previously served in the United States Navy. At Pharnext, Scott will continue to develop and maintain the Company's Quality strategy and ensure its operational execution. He will oversee the Quality activities in the areas of Manufacturing (Good Manufacturing Practices), Laboratory (Good Laboratory Practices) and Clinical (Good Clinical Practices) to ensure compliance with regulatory requirements. Scott will also be responsible for promoting a quality mindset across the Company and working with cross-departmental leadership to ensure the delivery of high-quality products and services.Price Target Changed • Nov 16Price target decreased to €2.50Down from €6.20, the current price target is provided by 1 analyst. New target price is 2,499,900% above last closing price of €0.0001. Stock is down 100% over the past year. The company is forecast to post a net loss per share of €1.29 next year compared to a net loss per share of €1.01 last year.Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Hugo Brugiere was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Major Estimate Revision • Oct 24Consensus revenue estimates fall by 42%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €4.13m to €2.40m. Forecast losses increased from -€0.68 to -€1.29 per share. Biotechs industry in France expected to see average net income growth of 8.4% next year. Consensus price target of €2.50 unchanged from last update. Share price fell 33% to €0.0002 over the past week.Reported Earnings • Oct 17First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 30% growth forecast for the Biotechs industry in France.Major Estimate Revision • Jun 29Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €3.90m to €4.13m. EPS estimate increased from -€0.77 per share to -€0.68 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target of €2.50 unchanged from last update. Share price fell 2.9% to €0.0034 over the past week.공시 • May 16Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of PXT3003Pharnext SA announced new results from the ongoing open-label follow-up extension study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’), the PLEO-CMT-FU trial, which followed the first double-blind, placebo controlled Phase III study, the PLEO-CMT trial. In January 2020 and April 2021, Pharnext reported results, based on previous data extraction from the PLEO-CMT and PLEO-CMT-FU trials, suggesting sustained safety and efficacy of PXT3003 in patients with mild-to-moderate CMT1A. The new results announced are derived from a data extraction performed on April 25th, 2022, which shows the continuous treatment effect for CMT1A patients treated with PXT3003 High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 60 months of total trial time (15 months of PLEO-CMT trial + 9 months of PLEO-CMT-FU trial period 1 + 36 months of PLEO-CMT-FU trial period 2). Please refer to an illustration of the first PXT3003 Phase III program design in the “About the PLEO-CMT-FU Trial” section below for more details.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 10 non-independent directors. Independent Non-Executive Director Piers Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Major Estimate Revision • Dec 07Consensus revenue estimates increase to €3.59mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from €2.57m to €3.59m. Forecast losses expected to reduce from -€1.16 to -€0.96 per share. Biotechs industry in France expected to see average net income growth of 3.4% next year. Consensus price target of €6.20 unchanged from last update. Share price fell 22% to €0.073 over the past week.Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).Reported Earnings • May 02Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1공시 • Apr 29Pharnext SA Announces New Results from an Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1APharnext SA announces new results from an interim analysis of an ongoing open-label follow-up extension study (‘PLEO-CMT-FU trial’) following the first double-blind, placebo-controlled Phase III study (‘PLEO-CMT trial’) of PXT3003 for the treatment of Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’). There is currently no approved drug treatment for CMT1A. In January 2020, the company reported interim results suggesting sustained safety and efficacy of PXT3003 in patients with mild-to-moderate CMT1A after 24 months of total trial time (PLEO-CMT and PLEO-CMT-FU Period 1 trials). The new results announced continue to show sustained treatment benefits for CMT1A patients treated with PXT3003 at High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 54 months of total trial time (double-blind + open-label). Highlights from an analysis of available data include: PXT3003 was safe and well tolerated. Data are consistent with observed safety profile in prior clinical trials. Data on the Overall Neuropathy Limitations Scale (‘ONLS’), which measures patients’ functional motor disability, are as follows (please refer to the diagram below for graphical illustration): During PLEO-CMT (double-blind Phase III study), patients treated with placebo on average declined on ONLS while patients treated with PXT3003 on average improved. The best efficacy signal was observed in the cohort of patients treated with PXT3003 HD. During PLEO-CMT-FU (open-label Phase III Extension study), on average patients improved on ONLS across all patient cohorts. Patients treated with placebo declined on ONLS during the double-blind phase, but then improved when switched to PXT3003 in the ongoing open-label phase. Patients treated with PXT3003 during the double-blind phase continue to improve when pursuing their treatment with PXT3003 in the ongoing open-label phase. New results with available ONLS data after 54 months of total trial time suggest a better efficacy signal with PXT3003 HD in this patient population.분석 기사 • Feb 01Pharnext's (EPA:ALPHA) Stock Price Has Reduced 66% In The Past Three YearsThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term Pharnext...분석 기사 • Dec 09We Might See A Profit From Pharnext SA (EPA:ALPHA) SoonWith the business potentially at an important milestone, we thought we'd take a closer look at Pharnext SA's...Reported Earnings • Nov 16First half 2020 earnings released: €0.63 loss per shareFirst half 2020 results: Net loss: €9.09m (loss narrowed 26% from 1H 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 17First half earnings releasedOver the last 12 months the company has reported total losses of €20.1m, with losses narrowing by 21% from the prior year.Is New 90 Day High Low • Oct 16New 90-day low: €3.03The company is down 15% from its price of €3.57 on 17 July 2020. The French market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €235 per share.Is New 90 Day High Low • Sep 25New 90-day low: €3.11The company is down 9.0% from its price of €3.40 on 26 June 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ALPHA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ALPHA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Pharnext S.C.A 배당 수익률 vs 시장ALPHA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ALPHA)n/a시장 하위 25% (FR)2.0%시장 상위 25% (FR)5.7%업계 평균 (Biotechs)2.2%분석가 예측 (ALPHA) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ALPHA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ALPHA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ALPHA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ALPHA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YFR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/02/18 16:05종가2025/02/14 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharnext S.C.A.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Soo RomanoffEdison Investment Research
New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Negative equity (-€32m). Earnings have declined by 7.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 2228x increase in shares outstanding). Revenue is less than US$1m (€172k revenue, or US$181k). Market cap is less than US$10m (€34.0 market cap, or US$35.8). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€10.1k market cap, or US$11.0k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.8m revenue, or US$2.0m).
공시 • May 09Pharnext SA, Annual General Meeting, Jun 10, 2024Pharnext SA, Annual General Meeting, Jun 10, 2024. Location: 14 rue de la republique, suresnes France
공시 • Feb 01Pharnext SA announced that it has received €41.188458 million in fundingPharnext SA announces private placement of 30,783,601,087 shares for an issue price of €0.001338 per shares for gross proceeds of €41,188,458 on January 31, 2024.
New Risk • Dec 27New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$173). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m).
공시 • Jan 04Pharnext Strengthens Its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of QualityPharnext SA announces the appointment of Scott Johnson as VP, Head of Quality. This appointment further strengthens the Company's Senior Leadership Team. Scott has more than 15 years of experience in quality management and compliance within the healthcare sector. He joins from Oyster Point Pharma, where he was Head of Quality Assurance. There, he established and implemented a comprehensive quality management system and oversaw all quality-related functions during the submission of an NDA application and successful launch of Oyster Point's first commercial product. Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance. He has also held roles at Johnson & Johnson and Warner Chilcott. Scott has a BA in Organizational Management from the Eastern University, St. David's, PA and previously served in the United States Navy. At Pharnext, Scott will continue to develop and maintain the Company's Quality strategy and ensure its operational execution. He will oversee the Quality activities in the areas of Manufacturing (Good Manufacturing Practices), Laboratory (Good Laboratory Practices) and Clinical (Good Clinical Practices) to ensure compliance with regulatory requirements. Scott will also be responsible for promoting a quality mindset across the Company and working with cross-departmental leadership to ensure the delivery of high-quality products and services.
Price Target Changed • Nov 16Price target decreased to €2.50Down from €6.20, the current price target is provided by 1 analyst. New target price is 2,499,900% above last closing price of €0.0001. Stock is down 100% over the past year. The company is forecast to post a net loss per share of €1.29 next year compared to a net loss per share of €1.01 last year.
Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Hugo Brugiere was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Major Estimate Revision • Oct 24Consensus revenue estimates fall by 42%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €4.13m to €2.40m. Forecast losses increased from -€0.68 to -€1.29 per share. Biotechs industry in France expected to see average net income growth of 8.4% next year. Consensus price target of €2.50 unchanged from last update. Share price fell 33% to €0.0002 over the past week.
Reported Earnings • Oct 17First half 2022 earnings releasedFirst half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 30% growth forecast for the Biotechs industry in France.
Major Estimate Revision • Jun 29Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €3.90m to €4.13m. EPS estimate increased from -€0.77 per share to -€0.68 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target of €2.50 unchanged from last update. Share price fell 2.9% to €0.0034 over the past week.
공시 • May 16Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of PXT3003Pharnext SA announced new results from the ongoing open-label follow-up extension study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’), the PLEO-CMT-FU trial, which followed the first double-blind, placebo controlled Phase III study, the PLEO-CMT trial. In January 2020 and April 2021, Pharnext reported results, based on previous data extraction from the PLEO-CMT and PLEO-CMT-FU trials, suggesting sustained safety and efficacy of PXT3003 in patients with mild-to-moderate CMT1A. The new results announced are derived from a data extraction performed on April 25th, 2022, which shows the continuous treatment effect for CMT1A patients treated with PXT3003 High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 60 months of total trial time (15 months of PLEO-CMT trial + 9 months of PLEO-CMT-FU trial period 1 + 36 months of PLEO-CMT-FU trial period 2). Please refer to an illustration of the first PXT3003 Phase III program design in the “About the PLEO-CMT-FU Trial” section below for more details.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 10 non-independent directors. Independent Non-Executive Director Piers Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Major Estimate Revision • Dec 07Consensus revenue estimates increase to €3.59mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from €2.57m to €3.59m. Forecast losses expected to reduce from -€1.16 to -€0.96 per share. Biotechs industry in France expected to see average net income growth of 3.4% next year. Consensus price target of €6.20 unchanged from last update. Share price fell 22% to €0.073 over the past week.
Reported Earnings • Oct 16First half 2021 earnings releasedFirst half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020).
Reported Earnings • May 02Full year 2020 earnings releasedFull year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1
공시 • Apr 29Pharnext SA Announces New Results from an Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1APharnext SA announces new results from an interim analysis of an ongoing open-label follow-up extension study (‘PLEO-CMT-FU trial’) following the first double-blind, placebo-controlled Phase III study (‘PLEO-CMT trial’) of PXT3003 for the treatment of Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’). There is currently no approved drug treatment for CMT1A. In January 2020, the company reported interim results suggesting sustained safety and efficacy of PXT3003 in patients with mild-to-moderate CMT1A after 24 months of total trial time (PLEO-CMT and PLEO-CMT-FU Period 1 trials). The new results announced continue to show sustained treatment benefits for CMT1A patients treated with PXT3003 at High Dose (‘HD’) in the PLEO-CMT-FU Period 2 trial with a data readout at 54 months of total trial time (double-blind + open-label). Highlights from an analysis of available data include: PXT3003 was safe and well tolerated. Data are consistent with observed safety profile in prior clinical trials. Data on the Overall Neuropathy Limitations Scale (‘ONLS’), which measures patients’ functional motor disability, are as follows (please refer to the diagram below for graphical illustration): During PLEO-CMT (double-blind Phase III study), patients treated with placebo on average declined on ONLS while patients treated with PXT3003 on average improved. The best efficacy signal was observed in the cohort of patients treated with PXT3003 HD. During PLEO-CMT-FU (open-label Phase III Extension study), on average patients improved on ONLS across all patient cohorts. Patients treated with placebo declined on ONLS during the double-blind phase, but then improved when switched to PXT3003 in the ongoing open-label phase. Patients treated with PXT3003 during the double-blind phase continue to improve when pursuing their treatment with PXT3003 in the ongoing open-label phase. New results with available ONLS data after 54 months of total trial time suggest a better efficacy signal with PXT3003 HD in this patient population.
분석 기사 • Feb 01Pharnext's (EPA:ALPHA) Stock Price Has Reduced 66% In The Past Three YearsThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term Pharnext...
분석 기사 • Dec 09We Might See A Profit From Pharnext SA (EPA:ALPHA) SoonWith the business potentially at an important milestone, we thought we'd take a closer look at Pharnext SA's...
Reported Earnings • Nov 16First half 2020 earnings released: €0.63 loss per shareFirst half 2020 results: Net loss: €9.09m (loss narrowed 26% from 1H 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 17First half earnings releasedOver the last 12 months the company has reported total losses of €20.1m, with losses narrowing by 21% from the prior year.
Is New 90 Day High Low • Oct 16New 90-day low: €3.03The company is down 15% from its price of €3.57 on 17 July 2020. The French market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €235 per share.
Is New 90 Day High Low • Sep 25New 90-day low: €3.11The company is down 9.0% from its price of €3.40 on 26 June 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.